Household water and home environments as sources of non-tuberculous mycobacteria in people with cystic fibrosis
Official title: Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home
Run by Research Center Borstel · NCT07369414 · Data updated 2026-11-12
This study will test whether household water, dust, and soil carry non-tuberculous mycobacteria that could infect people with cystic fibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Research Center Borstel Academic / other |
| Locations | 2 sites (Borstel, Schleswig-Holstein and 1 other locations) |
| Status | Recruiting |
| Started | February 16, 2026 |
| Main results expected | December 2028 |
| Study ends | December 2030 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07369414 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with confirmed cystic fibrosis (of any age) who can give informed consent, including about 60 with documented NTM per ATS/IDSA criteria and available clinical isolates and 60 without known NTM as controls.
✕Probably not a fit
People without cystic fibrosis, those unable to provide informed consent, or participants without available clinical isolates may not receive direct personal benefit since the study is observational.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter case-control study will enroll about 120 people with cystic fibrosis in Germany, including roughly 60 with current or past pulmonary NTM infection and 60 without known NTM. Environmental samples (water, dust, and soil) will be collected from participants' homes and analyzed by culture, PCR, and whole-genome sequencing. Findings in case and control households will be compared and any environmental isolates will be genetically compared with available clinical isolates. Standardized questionnaires and up to three years of follow-up for new NTM infections will be used to link environmental and behavioral risk factors to infection risk, and no additional medical procedures are required.
Why it matters
Potential benefit: If successful, the results could help patients by identifying household sources of NTM and informing practical prevention guidance to reduce future infections.
How similar studies have gone: Previous studies using environmental sampling and whole-genome sequencing have sometimes found matching household and patient strains, but results have been variable and not definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of cystic fibrosis (CF) * No age restriction (including minors with consent from legal guardians) * Written informed consent to participate in the study (or consent provided by a legal guardian for minors) * In the case of an NTM infection: diagnosis according to ATS/IDSA criteria and availability of a clinical NTM isolate Exclusion Criteria: * Lack of capacity to provide informed consent, refusal to participate, or withdrawal of informed consent
Where it's running
-
National and WHO-Supranational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center
Borstel, Schleswig-Holstein, Germany Recruiting -
Klinik für Pneumologie, Universitätsklinikum Essen
Essen, Germany Not yet recruiting
Study contacts
- Principal investigator: Alexander Mischnik, Prof. Dr. med. — National and WHO-Supranational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center
- Study coordinator: Margo Diricks, PhD
- Email: mdiricks@fz-borstel.de
- Phone: +49 4537 / 188-7540
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exercise-related breathing limits in adults with cystic fibrosis taking Elexacaftor‑Tezacaftor‑Ivacaftor
We will test how often adults with cystic fibrosis who are taking Elexacaftor‑Tezacaftor‑Ivacaftor reach ventilatory limits during a six‑minute walk.
-
Oropharyngeal suction and physiotherapy to detect lung bacteria in kids with chronic lung disease
A randomized study will test whether taking samples from the throat with suction, with or without prior physiotherapy, can reliably detect bacteria in children 5–18 with chronic lung disease, compared with standard sample methods.
-
Seeing if CFTR functioncan be restored in CF through patient cells with rare mutations
This study tests whether testing a patient’s own nasal cells in the lab can predict if CFTR-modulator therapies might help people with uncommon CF mutations.
-
Perceptions and Intentions Around a Change in CF Treatment
This study asks adults with cystic fibrosis currently on ETI whether they would switch to VTD if their doctor offered it and what factors influence that decision.
-
How the CF medicines elexacaftor, tezacaftor, and ivacaftor behave in the body
This study tests how the CF medicines elexacaftor, tezacaftor, and ivacaftor move through the body in patients with cystic fibrosis who are already taking the combination therapy.
-
Autogenic Drainage vs. Mechanical Chest Percussion in Children with Cystic Fibrosis
In children aged 6-12 with cystic fibrosis, this study tests whether autogenic drainage helps lung function and comfort more than mechanical percussion.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.